Compare AbbVie Inc (ABBV) vs Block Inc (XYZ) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

XYZ (Block, Inc.) trades at $77.56, down 1.61% today, with a bullish technical signal from moving averages and strong analyst consensus (74% buy ratings). Recent earnings show mixed results with Q1 2026 beating expectations, while cash flow turned negative in 2025 due to heavy investing. The company continues expanding its Square platform through AI integrations and enterprise partnerships, positioning for growth in digital payments.

Outlook remains positive with a $87.71 consensus price target, though high P/E of 61.66 and declining net income margins pose valuation concerns. Key risks include execution on AI initiatives and competitive pressure in fintech. Institutional sentiment is supportive, but investors should monitor Q2 2026 earnings due August 5, 2026 for confirmation of growth trajectory.